MY148844A - Fumarate salt of (alpha s, beta r)-6- bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol - Google Patents

Fumarate salt of (alpha s, beta r)-6- bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol

Info

Publication number
MY148844A
MY148844A MYPI20092284A MYPI20092284A MY148844A MY 148844 A MY148844 A MY 148844A MY PI20092284 A MYPI20092284 A MY PI20092284A MY PI20092284 A MYPI20092284 A MY PI20092284A MY 148844 A MY148844 A MY 148844A
Authority
MY
Malaysia
Prior art keywords
alpha
beta
quinolineethanol
naphthalenyl
dimethylamino
Prior art date
Application number
MYPI20092284A
Other languages
English (en)
Inventor
Hegyi Jean Francois Alexandre Lucas
Aelterman Wim Albert Alex
Lang Yolande Lydia
Stokbroekx Sigrid Carl Maria
Leys Carina
Remoortere Peter Jozef Van Maria
Faure Anne
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37983588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY148844(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MY148844A publication Critical patent/MY148844A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
MYPI20092284A 2006-12-05 2007-12-03 Fumarate salt of (alpha s, beta r)-6- bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol MY148844A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06125443 2006-12-05

Publications (1)

Publication Number Publication Date
MY148844A true MY148844A (en) 2013-06-14

Family

ID=37983588

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20092284A MY148844A (en) 2006-12-05 2007-12-03 Fumarate salt of (alpha s, beta r)-6- bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol

Country Status (34)

Country Link
US (1) US8546428B2 (enExample)
EP (1) EP2086940B1 (enExample)
JP (2) JP2010511663A (enExample)
KR (1) KR101514700B1 (enExample)
CN (2) CN105012303A (enExample)
AP (1) AP2498A (enExample)
AR (1) AR064149A1 (enExample)
AU (1) AU2007328945B2 (enExample)
BR (1) BRPI0719693A2 (enExample)
CA (1) CA2668512C (enExample)
CL (1) CL2007003472A1 (enExample)
CY (1) CY1113594T1 (enExample)
DK (1) DK2086940T3 (enExample)
EA (1) EA017091B9 (enExample)
ES (1) ES2387923T3 (enExample)
HK (1) HK1214513A1 (enExample)
HR (1) HRP20120639T1 (enExample)
IL (1) IL199077A (enExample)
JO (1) JO2973B1 (enExample)
ME (1) ME01456B (enExample)
MX (1) MX2009005909A (enExample)
MY (1) MY148844A (enExample)
NO (1) NO342773B1 (enExample)
NZ (1) NZ576485A (enExample)
PE (1) PE20081350A1 (enExample)
PL (1) PL2086940T3 (enExample)
PT (1) PT2086940E (enExample)
RS (1) RS52408B (enExample)
SI (1) SI2086940T1 (enExample)
TW (1) TWI417098B (enExample)
UA (1) UA97813C2 (enExample)
UY (1) UY30762A1 (enExample)
WO (1) WO2008068231A1 (enExample)
ZA (1) ZA200903907B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
CZ2014708A3 (cs) 2014-10-16 2016-04-27 Zentiva, K.S. Soli Bedaquilinu
WO2016120258A1 (en) * 2015-01-27 2016-08-04 Janssen Pharmaceutica Nv Dispersible compositions
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
CZ2015391A3 (cs) 2015-06-09 2016-12-21 Zentiva, K.S. Sůl bedaquilinu s kyselinou citronovou
US10196360B2 (en) * 2015-10-20 2019-02-05 Zhejiang Hisun Pharmaceutical Co., Ltd. Crystal forms of bedaquiline fumarate and preparation methods therefor
HRP20241015T1 (hr) * 2016-07-20 2024-11-08 Novartis Ag Derivati aminopiridina i njihova uporaba kao selektivnih alk-2 inhibitora
CN106316943A (zh) * 2016-07-27 2017-01-11 重庆华邦制药有限公司 富马酸贝达喹啉晶型化合物的精制方法
EP4356968A3 (en) 2017-07-14 2024-07-10 JANSSEN Pharmaceutica NV Long-acting formulations
US20220023282A1 (en) * 2018-12-13 2022-01-27 Mannkind Corporation Compositions of Bedaquiline, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them
JP2022516671A (ja) 2019-01-09 2022-03-01 ヤンセン ファーマシューティカ エヌ．ベー． 非結核性抗酸菌症の処置における組合せ
WO2020161743A1 (en) * 2019-02-08 2020-08-13 Mylan Laboratories Limited Process for the preparation of bedaquiline fumarate
KR102303635B1 (ko) * 2020-07-01 2021-09-17 동아에스티 주식회사 (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
CN111888477B (zh) * 2020-09-15 2023-03-07 北京福元医药股份有限公司 一种贝达喹啉药物制剂
TW202233168A (zh) 2020-11-12 2022-09-01 比利時商健生藥品公司 治療非結核分枝桿菌疾病的藥物組分之組合
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
CN117399070B (zh) * 2022-07-07 2025-06-24 上海交通大学 含有螯合配体的双手性金属协同催化体系及其不对称合成贝达喹啉的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
GB8824392D0 (en) * 1988-10-18 1988-11-23 Ciba Geigy Ag Dispersible formulation
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
US5965572A (en) 1996-10-28 1999-10-12 The United States Of America As Respresented By The Secretary Of The Army Methods for treating antibiotic-resistant infections
CZ300261B6 (cs) * 1996-10-30 2009-04-01 Eli Lilly And Company Použití hydrochloridové soli raloxifenu pro prípravu léciva pro prevenci rakoviny prsu
US6819464B2 (en) * 2002-06-19 2004-11-16 Seiko Epson Corporation Optical modulator, optical device and projector
ATE463482T1 (de) * 2002-07-25 2010-04-15 Janssen Pharmaceutica Nv Chinolinderivate und deren verwendung als mycobakterielle inhibitoren
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
AP2037A (en) * 2004-05-28 2009-10-09 Janssen Pharmaceutica Nv Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
WO2006024667A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
JP2006182755A (ja) * 2004-12-24 2006-07-13 Janssen Pharmaceut Nv 潜伏性結核の処置

Also Published As

Publication number Publication date
ZA200903907B (en) 2013-08-28
DK2086940T3 (da) 2012-08-20
EA017091B9 (ru) 2014-10-30
US20100028428A1 (en) 2010-02-04
HK1214513A1 (zh) 2016-07-29
PE20081350A1 (es) 2008-09-18
AP2498A (en) 2012-10-19
TW200838527A (en) 2008-10-01
EA017091B1 (ru) 2012-09-28
SI2086940T1 (sl) 2012-09-28
UA97813C2 (uk) 2012-03-26
WO2008068231A1 (en) 2008-06-12
JP5894239B2 (ja) 2016-03-23
JO2973B1 (en) 2016-03-15
US8546428B2 (en) 2013-10-01
EP2086940A1 (en) 2009-08-12
EA200970532A1 (ru) 2009-10-30
UY30762A1 (es) 2008-07-03
KR101514700B1 (ko) 2015-04-24
NZ576485A (en) 2012-01-12
PL2086940T3 (pl) 2012-10-31
EP2086940B1 (en) 2012-05-16
CN105012303A (zh) 2015-11-04
CN101547904A (zh) 2009-09-30
ES2387923T3 (es) 2012-10-04
PT2086940E (pt) 2012-08-09
AP2009004870A0 (en) 2009-06-30
KR20090087020A (ko) 2009-08-14
AU2007328945B2 (en) 2014-04-03
RS52408B (sr) 2013-02-28
NO342773B1 (no) 2018-08-06
IL199077A (en) 2016-09-29
HRP20120639T1 (hr) 2012-08-31
MX2009005909A (es) 2009-06-16
AU2007328945A1 (en) 2008-06-12
CA2668512A1 (en) 2008-06-12
BRPI0719693A2 (pt) 2013-12-24
NO20092535L (no) 2009-08-06
ME01456B (me) 2014-04-20
JP2015028049A (ja) 2015-02-12
CY1113594T1 (el) 2016-06-22
CA2668512C (en) 2015-03-24
AR064149A1 (es) 2009-03-18
CL2007003472A1 (es) 2008-08-22
TWI417098B (zh) 2013-12-01
JP2010511663A (ja) 2010-04-15

Similar Documents

Publication Publication Date Title
MY148844A (en) Fumarate salt of (alpha s, beta r)-6- bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
UA96449C2 (en) Stable laquinimod preparations
UA94942C2 (ru) Фармацевтические композиции с ингибиторами dpp iv
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
MX2009004746A (es) Derivados de 1,2,4-triazol como inhibidores del receptor sigma.
MX2009011276A (es) Inhibidor de dpp-iv que incluye el grupo beta-amino, metodo para la preparacion del mismo y composicion farmaceutica que contiene el mismo para prevenir y tratar una diabetes o una obesidad.
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів
MX2009004745A (es) Derivados de 1,2,3-triazol como inhibidores del receptor sigma.
SG178975A1 (en) Indenone derivative and pharmaceutical composition comprising same
MX2009013501A (es) Compuestos piperidinicos y sus usos.
TW200745122A (en) New compounds I
TW200731975A (en) Novel combinations of medicaments for the treatment of respiratory diseases
WO2010061220A3 (en) Novel processes and pure polymorphs
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases
TW200744993A (en) Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid
WO2009108017A3 (en) New pyruvate derivatives with neuroprotective effect, process for preparing the same and pharmaceutical composition comprising the same
TNSN08242A1 (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
UA93864C2 (ru) Соединения нафталина, способ их получения и фармацевтическая композиция, которая содержит их
WO2010061219A3 (en) Polymorphs
MY148611A (en) Imino-imidazo-pyridine derivatives having antithrombotic activity
GB0615105D0 (en) Novel compounds
MX2009003930A (es) Novedoso cristal de (s)-(+)-2-(2-clorofenil)-2-hidroxi-etil carbamato.